Most Definitive & Accurate Study Of Immuno-oncology Development Trends and Opportunities

Researchmoz added Most up-to-date research on "Most Definitive & Accurate Study Of Immuno-oncology Development Trends and Opportunities" to its huge collection of research reports.

Immuno-oncology (IO) is the treatment of cancer with therapies that stimulate or suppress the bodys own immune system. Several distinct modalities of IO therapy exist, including bispecific T-cell engaging monoclonal antibodies, cellular immunotherapy and adoptive cellular therapy, cancer vaccines, checkpoint modulating monoclonal antibodies, and oncolytic viruses.

This report provides an overview of current clinical development trends for IO within the 8MM (France, Germany, Italy, Spain, UK, US, Japan, China), including a history of recent approvals, indications currently being explored for IO agents of all modalities, targets being selected for IO therapies, and combination strategies being investigated for approved IO agents. 

In addition, the report provides disease overviews, epidemiology, current recommended treatment regimens and IO approvals, and IO clinical trial trends for 17 indications which GlobalData has identified as representing the largest commercial opportunities for IO agents. Clinical trial trends analyze ongoing trials by sponsor type and modality, as well as ongoing combination trials for approved IO therapies.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1956812

Scope
This report combines primary research from a cross-specialty panel of oncology experts with in-house analyst expertise to provide an assessment of the development landscape. Components of the slide deck include primary and secondary research - 
- Quotes from 13 US-, 5EU-, and Japan-based key opinion leaders
- Summary of IO product definitions and classifications
- Overview of development opportunities for IO agents across indications, including emerging indications and clinical targets, and novel combination strategies
- Outline of 17 key indications for IO agents, including current EU and US guideline recommendations, IOs current place in the treatment algorithm, and a review of ongoing clinical trials
- Call-outs of key information and details
- Insight from GlobalDatas specialist oncology analysts.

Browse TOC @ https://www.researchmoz.us/immuno-oncology-development-trends-and-opportunities-report.html/toc

Reasons to buy
- Develop business strategies by understanding the trends shaping and driving IO in the 8MM.
- Drive revenues by understanding the key trends, innovative combination strategies and indications likely to impact the IO market in the future.
- Design your development strategy through a review of potential novel targets or combinations across indications.
- Organize your sales and marketing efforts by understanding IO combination approaches across indications that present maximum opportunities for consolidations, investments, and strategic partnerships.
- Develop strategies by understanding expert perceptions of unmet needs in key indications in oncology, and the potential for IO agents to meet those needs.

At A CAGR Of 3.38%, Global Cancer Supportive Care Market Will Expand For The Period From 2017 - 2021

Researchmoz added Most up-to-date research on "At A CAGR Of 3.38%, Global Cancer Supportive Care Market Will Expand For The Period From 2017 - 2021" to its huge collection of research reports.

Cancer supportive care drugs are used for the treatment of adverse effects caused due to the cancer treatment such as chemotherapy-induced anemia, CINV, bone metastasis, cancer pain, and others. Various class of drugs are used as cancer supportive care drugs. Some of the major drug class that involves in cancer supportive care are antiemetic drugs, erythropoietin-stimulating agents, granulocyte-stimulating agents, analgesics, and others.

Technavios analysts forecast the global cancer supportive care market to grow at a CAGR of 3.38% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global cancer supportive care market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in cancer supportive care market.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Cancer Supportive Care Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1331127

Key vendors
Amgen
Helsinn Healthcare
Johnson &Johnson
Merck

Other prominent vendors
F. Hoffmann-La Roche
GlaxoSmithKline
Heron Therapeutics
Kyowa Hakko Kirin
Novartis
TESARO
Teva Pharmaceutical Industries

Market driver
Large number of side effects associated with the cancer treatment
For a full, detailed list, view our report

Browse TOC @ https://www.researchmoz.us/global-cancer-supportive-care-market-2017-2021-report.html/toc

Market challenge
Rising popularity of targeted therapies for the treatment of cancer in developed countries
For a full, detailed list, view our report

Market trend
Advent of biosimilars in cancer-associated treatment
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?

Global Revenue For The Oncology Market Forecast To Grow At A CAGR Of 10.66%, From $118.6 Billion In 2016 To $241.0 Billion In 2023

Researchmoz added Most up-to-date research on "Global Revenue For The Oncology Market Forecast To Grow At A CAGR Of 10.66%, From $118.6 Billion In 2016 To $241.0 Billion In 2023" to its huge collection of research reports.

Global Oncology Market

In 2012, there were 32.6 million people living with any type of cancer within five years of diagnosis. These are generally incurable once they progress to the stage where they are unresectable.

Chemotherapy compounds are a mainstay treatment for cancers of all types, at various disease stages. In a typical course of therapy for cancer, multiple chemotherapy compounds are administered sequentially in combination regimens, as an adjunct to surgery and radiation therapy. Chemotherapy drugs are cytotoxic to dividing cells, meaning that they act on both healthy and malignant tissues and are fairly toxic. However, they exert more damage on malignant tissue than healthy tissue due to the rapid cell cycle of cancer cells. The key cancer indications of this report are breast, colorectal, lung, and prostate and hematological cancers.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1245341

A number of common etiologic factors have been strongly characterized as raising the risk of developing cancer, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

There has been a shift towards developing targeted therapies, such as mAbs and cell therapies. Targeted therapies, by their nature, have less toxicity associated with their use and as a result can be administered to more cancer patients, who are commonly elderly and have co-morbidities, therefore increasing the overall survival of this group and the number of treatment cycles they may receive. The most commercially successful oncology treatments are mAbs such as MabThera/Rituxan, Avastin and Herceptin.

Browse TOC @ https://www.researchmoz.us/global-oncology-market-to-2023-robust-growth-driven-by-rising-prevalence-and-increased-uptake-of-immune-checkpoint-inhibitors-report.html/toc

Scope

• Global revenue for the oncology market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.66%, from $118.6 billion in 2016 to $241.0 billion in 2023. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
• The oncology pipeline is large and fairly diverse and contains 7,773 products. How does the composition of the pipeline compare with that of the existing market? What are the most popular types of molecule type and molecular target in the pipeline?
• What mechanisms of action and molecule types are most common for pipeline products being trialed in the various key indications? 
• How will the market shares and CAGRs of the top 20 pharma companies compare within oncology?
• What proportion of the key players’ revenues will be attributable to oncology products?

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
• Visualize the composition of the oncology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
• Analyze the oncology pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
• Understand the growth in patient epidemiology and market revenue for the oncology market globally and across the key players and product types
• Stratify the market in terms of the generic and premium product revenue split between oncology products and assess the role of these product types in the treatment of the various cancers
• Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals

Global Companion Diagnostic Tests in Oncology Market During 2017 - 2025: Rising Incidences of Recurring Malignancy to Supplement Adoption

Researchmoz added Most up-to-date research on "Global Companion Diagnostic Tests in Oncology Market During 2017 - 2025: Rising Incidences of Recurring Malignancy to Supplement Adoption" to its huge collection of research reports.

Companion diagnostics (CDx) are the tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with a targeted therapeutic area. These tests are an indicative measure of the patient sub-population that will be benefitted from the suggested drug / therapy, and differentiates the non-responder patients from the one’s who will respond to the treatment option. Hence, these diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to pharmaceutical companies, and the patients as well. Of late, many leading pharmaceutical companies are focusing on regulating the costs incurred in the drug discovery, development and commercialization process. This effort involves the development of companion diagnostic along with a targeted therapeutic area, and this has led to increasing collaborations between pharmaceutical and medical device companies, to co-develop a drug with companion diagnostic test. The tremendous research in the field of oncology, has led to the discovery of numerous biomarkers facilitating disease diagnosis and treatment, and these are some major factors contributing to the increasing demand for personalized medicine, and companion diagnostics tests in oncology.

The market overview section of the report comprises qualitative analysis of the overall companion diagnostic tests in oncology market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, market opportunity analysis for detection techniques, biomarker, and type of cancer, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics.

Global Companion Diagnostic Tests in Oncology Market: Segmentation
The global companion diagnostic tests in oncology market has been segmented on the basis of detection technique, biomarker, cancer type, and end-user. On the basis of detection technique, the global companion diagnostic tests in oncology market is segmented into protein detection technique, DNA detection technique, and other detection techniques.  The DNA detection techniques are further segmented into polymerase chain reaction, next generation sequencing, and in situ hybridization detection techniques. The biomarker segment of the global companion diagnostic tests in oncology market is segmented into EGFR, HER2, KRAS, BRAF V600E, and other biomarkers. The cancer type segment of the global companion diagnostic tests in oncology market is further segmented into breast cancer, lung cancer, liver cancer, melanoma, colorectal cancer, and other cancers. The end-user segment includes pharmaceutical & biotechnology companies, medical device companies, research institutes, and other end-users. The market for these detection techniques, biomarker, cancer types and end users has been extensively analyzed on the basis of factors such as incidence, prevalence of diseases, usage pattern of detection techniques, sales revenue of the tests, geographic presence of the market players and technological developments. The market size and forecast in terms of revenue (US$ Mn) for each of these segments have been provided for the period 2015 to 2025, considering 2016 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2017 to 2025.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1166572

Global Companion Diagnostic Tests in Oncology Market: Regional Outlook
Geographically, the companion diagnostic tests in oncology market has been segmented into five regions namely; North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of detection techniques, biomarker, cancer type, and end-user along with the CAGR (%) for the forecast period 2017-2025.

Global Companion Diagnostic Tests in Oncology Market: Competitive Landscape
The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global companion diagnostic tests in oncology market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global Companion Diagnostic Tests in Oncology market such as F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global companion diagnostic tests in oncology market is segmented as follows:

Global Companion Diagnostic Tests in Oncology Market, By Detection Technique

• Protein Detection
• DNA Detection
• Polymerase Chain Reaction (PCR)
• Next Gen Sequencing (NGS)
• In Situ Hybridization
• Fluorescence In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Others

Global Companion Diagnostic Tests in Oncology Market, by Biomarker

• EGFR
• KRAS
• HER2
• BRAF V600E
• Others

Global Companion Diagnostic Tests in Oncology Market, by Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Liver Cancer
• Melanoma
• Others

Global Companion Diagnostic Tests in Oncology Market, by End Users

• Pharmaceutical & Biotechnology Companies
• Medical Device Companies
• Research Institutes
• Others

Global Companion Diagnostic Tests in Oncology Market, by Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Browse More Details @ http://www.researchmoz.us/companion-diagnostic-tests-in-oncology-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html

Global Companion Diagnostic Tests in Oncology Market From 2017 - 2025: Rising Incidences of Recurring Malignancy to Supplement Adoption

Researchmoz added Most up-to-date research on "Global Companion Diagnostic Tests in Oncology Market From 2017 - 2025: Rising Incidences of Recurring Malignancy to Supplement Adoption" to its huge collection of research reports.

Companion diagnostics (CDx) are the tests or assays intended to assist physicians in making effective treatment decisions based on the patient response to the ongoing treatment with a targeted therapeutic area. These tests are an indicative measure of the patient sub-population that will be benefitted from the suggested drug / therapy, and differentiates the non-responder patients from the one’s who will respond to the treatment option. Hence, these diagnostic tests ensure the commercialization of safer and efficient targeted therapeutics with minimal or no side effects, while ensuring economic benefits to pharmaceutical companies, and the patients as well. Of late, many leading pharmaceutical companies are focusing on regulating the costs incurred in the drug discovery, development and commercialization process. This effort involves the development of companion diagnostic along with a targeted therapeutic area, and this has led to increasing collaborations between pharmaceutical and medical device companies, to co-develop a drug with companion diagnostic test. The tremendous research in the field of oncology, has led to the discovery of numerous biomarkers facilitating disease diagnosis and treatment, and these are some major factors contributing to the increasing demand for personalized medicine, and companion diagnostics tests in oncology.

The market overview section of the report comprises qualitative analysis of the overall companion diagnostic tests in oncology market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, market opportunity analysis for detection techniques, biomarker, and type of cancer, and key industry developments has also been provided. Key industry developments include the major events occurred in past decade and are expected to occur during the forecast period which are likely to affect the market dynamics.

Global Companion Diagnostic Tests in Oncology Market: Segmentation
The global companion diagnostic tests in oncology market has been segmented on the basis of detection technique, biomarker, cancer type, and end-user. On the basis of detection technique, the global companion diagnostic tests in oncology market is segmented into protein detection technique, DNA detection technique, and other detection techniques.  The DNA detection techniques are further segmented into polymerase chain reaction, next generation sequencing, and in situ hybridization detection techniques. The biomarker segment of the global companion diagnostic tests in oncology market is segmented into EGFR, HER2, KRAS, BRAF V600E, and other biomarkers. The cancer type segment of the global companion diagnostic tests in oncology market is further segmented into breast cancer, lung cancer, liver cancer, melanoma, colorectal cancer, and other cancers.

The end-user segment includes pharmaceutical & biotechnology companies, medical device companies, research institutes, and other end-users. The market for these detection techniques, biomarker, cancer types and end users has been extensively analyzed on the basis of factors such as incidence, prevalence of diseases, usage pattern of detection techniques, sales revenue of the tests, geographic presence of the market players and technological developments. The market size and forecast in terms of revenue (US$ Mn) for each of these segments have been provided for the period 2015 to 2025, considering 2016 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2017 to 2025.

Global Companion Diagnostic Tests in Oncology Market: Regional Outlook
Geographically, the companion diagnostic tests in oncology market has been segmented into five regions namely; North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size and forecast for each region has been provided for the period 2015 to 2025, in terms of detection techniques, biomarker, cancer type, and end-user along with the CAGR (%) for the forecast period 2017-2025.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1166572

Global Companion Diagnostic Tests in Oncology Market: Competitive Landscape
The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global companion diagnostic tests in oncology market, in terms of percentage share in 2016 has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. The report concludes with the profiles of major players in the global Companion Diagnostic Tests in Oncology market such as F. Hoffman LA Roche Ltd., QIAGEN, Illumina, Inc., Abbott, Agilent Technologies, Inc., Genomic Health, Inc., bioMerieux SA, BioGenex, AGENDIA NV, Siemens Healthcare GmBH, and Thermo Fisher Scientific, Inc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

The global companion diagnostic tests in oncology market is segmented as follows:

Global Companion Diagnostic Tests in Oncology Market, By Detection Technique

• Protein Detection
• DNA Detection
• Polymerase Chain Reaction (PCR)
• Next Gen Sequencing (NGS)
• In Situ Hybridization
• Fluorescence In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Others

Global Companion Diagnostic Tests in Oncology Market, by Biomarker

• EGFR
• KRAS
• HER2
• BRAF V600E
• Others

Global Companion Diagnostic Tests in Oncology Market, by Cancer Type

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Liver Cancer
• Melanoma
• Others

Global Companion Diagnostic Tests in Oncology Market, by End Users

• Pharmaceutical & Biotechnology Companies
• Medical Device Companies
• Research Institutes
• Others

Global Companion Diagnostic Tests in Oncology Market, by Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Browse More Details @ http://www.researchmoz.us/companion-diagnostic-tests-in-oncology-market-global-industry-analysis-size-share-growth-trends-and-forecast-2017-2025-report.html

Clinical Trials On Global Cancer Gene Therapy Market Will Expand At A CAGR Of 20.63% During The Period 2017 - 2021

Researchmoz added Most up-to-date research on "Clinical Trials On Global Cancer Gene Therapy Market Will Expand At A CAGR Of 20.63% During The Period 2017 - 2021" to its huge collection of research reports.

Cancer gene therapy is the treatment of cancer through gene therapy. The therapy uses genetically engineered vectors mostly viruses to deliver a gene into the individual's body. It can be used for both the prevention and treatment of disease. The major therapies used for the treatment are oncolytic virotherapy, gene transfer, and gene-induced immunotherapy. The rising prevalence rate of cancer has been a huge challenge for the global economies as the disease leads to high rate of mortality and economic losses.

Technavios analysts forecast the global cancer gene therapy market to grow at a CAGR of 20.63% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global cancer gene therapy market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Cancer Gene Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
Adaptimmune
bluebird bio
Celgene
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
SynerGene Therapeutics

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=1293336

Other prominent vendors
Altor BioScience
Amgen
argenx
BioCancell
GlaxoSmithKline
Merck
OncoGenex Pharmaceuticals
Transgene

Market driver
Rising geriatric population
For a full, detailed list, view our report

Market challenge
High cost of gene therapy treatment
For a full, detailed list, view our report

Market trend
Favorable government regulations for gene therapy programs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?

Browse More Details @ http://www.researchmoz.us/global-cancer-gene-therapy-market-2017-2021-report.html

Key Coverage And Benefits Of Global Osteosarcoma Market: Insights, Epidemiology and Market Forecast, 2023

Researchmoz added Most up-to-date research on "Key Coverage And Benefits Of Global Osteosarcoma Market: Insights, Epidemiology and Market Forecast, 2023" to its huge collection of research reports.

DelveInsights Osteosarcoma - Market Insights, Epidemiology and Market Forecast-2023 Reports provides an overview of the disease and global market trends of the Osteosarcoma for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the therapeutics market revenue; average cost of therapy, treatment practice and Osteosarcoma forecasted market share for ten years to 2023 segmented by seven major markets. In addition, the report also includes global forecast of epidemiology of Osteosarcoma till 2023.

Key Coverage and Benefits
The report will help in developing business strategies by understanding the trends shaping and driving the global Osteosarcoma market.
Identifying patient populations in the global Osteosarcoma market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Osteosarcoma therapeutics in each of the markets covered.
To understand the future market competition in the global Osteosarcoma therapeutics market and Insightful review of the key market drivers and barriers.

Scope
Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2013-2023.
It also provides Osteosarcoma for United States, EU5 and Japan from 2013 and forecasted Market to 2023.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=774553

Table of Contents

Osteosarcoma overview
Pathophysiology
Symptoms of disease
Etiology of disease
Diagnosis of disease
Treatment of disease
Overview of Marketed drugs
Drug Description
Mechanism of Action
Pharmacokinetics Properties
Marketed Details
Patent Information
Patent Exclusivity Expiry Assessment United States (US)
Patents Details
Historical and Forecasted sales of marketed molecules in the Global Osteosarcoma Market
Global Epidemiology of Osteosarcoma Forecasted to 2023
Global Market (2013-2015)
Global Forecasted Market (2016-2023)
Global Market by Geography
Market of US (2013-2015)
Forecasted Market of US (2016-2023)

Browse More Details @ http://www.researchmoz.us/osteosarcoma-market-insights-epidemiology-and-market-forecast-2023-report.html

Clinical And Preclinical Combination Study: Competitor Analysis Of Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology

ResearchMoz presents this most up-to-date research on "Clinical And Preclinical Combination Study: Competitor Analysis Of Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology".

Competitor Analysis: Inhibitory and Stimulatory Immunomodulators in Immuno-Oncology
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).

Purchase of this product includes a 6-month online access to the data of the reports and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:
Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others
Competitor Analysis: Activators of Immune Checkpoints CD40, GITR, OX40, 4-1BB, CD27 & ICOS
Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-B/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others

Targets of Immunomodulators are inhibitory as well as stimulatory immune checkpoints and from the tumor microenvironment:
Negative Immune Checkpoints:

PD-1(programmed cell death 1
PD-L1(programmed cell death ligand 1 (PD-L1)
(Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
(Lymphocyte Activation Gene 3; CD223)
(T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
(V-region Ig-containing Suppressor of T-cell Activation) Receptor
(Carcino-Embryonic Antigen Cell Adhesion Molecule 1)
BTLA (B- and T-Lymphocyte Attenuator)
GARP (Glycoprotein A Repetitions Predominant)
TIGIT(T-cell Immunoreceptor with Ig and ITIM domains)
IL-10(Interleukin-10)
B7-H3(CD273)

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=895857

Stimulatory Immune Checkpoints:
CD40 (TNFSFR5)
GITR(Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
OX40(CD134; TNFSFR4)
4-1BB(CD137; TNFSFR9)
CD27 (TNFSFR7)
ICOS(Inducible Co-Stimulator)

Immunosuppressive tumor microenvironment:
IDO (Indoleamine 2,3-dioxygenase
TDO ( Tryptophan 2,3 dioxygenase)
TGF-B/R ( Transforming Growth Factor beta/Receptor)
CXCR4 (Chemokine Receptor Type 4)
CSF-1R ( Colony Stimulating Factor-1 Receptor)
CD47 SIRPa (Signal Regulatory Protein Alpha)
Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
STING (STimulator of INterferon Genes) Receptor
Others ( e.g. arginase)

More than 90 unique molecules (mostly antibodies) targeting inhibitory and stimulatory immunomodulators are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further 31 molecules are undergoing IND-enabling studies.

The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=895857

Worldwide Analysis Of Radiology Oncology Surgical Robots Market: Shares, Strategies and Forecasts From 2016 to 2022

Researchmoz added Most up-to-date research on "Worldwide Analysis Of Radiology Oncology Surgical Robots Market: Shares, Strategies and Forecasts From 2016 to 2022" to its huge collection of research reports.

The 2016 study has 557 pages, 82 tables and figures. Worldwide Radiology Oncology surgical robot markets are poised to achieve significant growth as next generation systems provide a way to improve traditional open surgery and use radiology for cancer surgery. New systems pinpoint the delivery of radiation precisely, eliminating the radiological overdosing that has been such a problem previously, limiting the quantity of radiation that can be delivered.

Radiosurgery robots take cancer surgery far beyond what has been available, promising a cure for cancer. Radiology oncology surgical robots use mechanical mobility and continuous image guidance to remove tumors. The Accuray CyberKnife® robotic system follows the oncology target throughout treatment, intelligently delivering sub-millimeter precision, sparing healthy tissue. A robotic manipulator and a compact, lightweight linear accelerator, can deliver beams from thousands of non-coplanar, isocentric or non-isocentric angles. Treatments have excellent tumor coverage, steep dose gradients, and tight dose conformality.

The radiation oncology market is growing globally due to a number of factors centered around the aging of the population and the benefits accrued from new technology. The number of new cancer cases diagnosed annually is projected to increase from 14.9 million in 2015 to 20 million by 2025. The increase in new cases is due to a steadily aging population. Both developed and developing countries have aging populations.

Technology advances improve the precision and applicability of radiotherapy and radiosurgery. Expanding uses of radiotherapy and radiosurgery equipment occur because the units are able to treat a broader range of cases. Advances in hardware and software are creating a market for replacing an aging installed base. New designs are able to deliver higher standards of care.
The rise in cancer cases, together with the increase in sophistication of new treatment protocols, have created demand for more automated products. Automation depends on integration of several devices into clinically practical systems. Integrated systems make treatments rapid and cost effective.

Technology advances lead to improvements in patient care. The availability of advanced, automated and efficient clinical tools in radiation therapy has brought more precise forms of radiotherapy treatment (IMRT, IGRT, VMAT, SRS, SBRT, brachytherapy and proton therapy). Technology includes the EDGE™ and Truebeam™, and the Accuray TomoTherapy H Series and CyberKnife M6 platforms that enable treatments that reduce treatment times and increase patient throughput .

International markets are under-equipped to address the growing cancer incidence. Patients in many foreign countries must frequently endure long waits for radiotherapy.
9,000 additional treatment machines will be required by 2020 in developing countries. China, India and Brazil are estimated to require over 3,800, 1,200 and 400 additional machines. Demand in emerging markets, coupled with ever increasing incidences of cancer, represent additional drivers for continued growth.

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=507309

Radiology oncology surgical robot market driving forces relate to an opportunity to achieve change in medical practice regarding the treatment of cancer. Change would lead to utilization of stereotactic body radiosurgery more regularly as an alternative to surgery or other treatments. Radiosurgery is poised to revolutionize the treatment of cancer by eradicating tumors while not harming surrounding healthy tissue.

The ability to use high doses of radiation to precisely eliminate a tumor while leaving healthy tissue unharmed is compelling. It means that high doses of radiation can be delivered without killing the person, that doses of radiation delivered can be enough to kill the cancer without killing the person, this represents a change in what has been possible previously.
The Varian, Elekta, and Accuray radiology oncology surgical devices offer robust clinical treatment capabilities. Flexibility of the Accuray InCise™ Multileaf Collimator and robotic delivery permit treatment of tumors previously thought untreatable. With radiosurgery and SBRT cancer can be treated efficiently and effectively. The device offers accuracy.

The complete report provides a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success, challenges, and strategies in each segment and sub-segment. The reports cover markets for Radiology Oncology robotic surgery medical specialties and sub-specialties.

Companies Profiled

• Market Leaders
• Varian
• Elekta
• Accuray

Market Participants

• Best Theratronics, Ltd
• Brainlab AG
• Mitsubishi Heavy Industries
• ViewRay 

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=507309

Pharmaceutical Report On Dakogen - Drug Insights For 2017 | ResearchMoz

Researchmoz added Most up-to-date research on "Pharmaceutical Report On Dakogen - Drug Insights For 2017 | ResearchMoz" to its huge collection of research reports.

The Report will be Dispatched in 3 working days. DelveInsights pharmaceuticals report, Dakogen - Drug Insights, 2014 provides Dakogen marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data and information sourced from DelveInsight proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by DelveInsight team of industry experts. 

Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=218754

Table Of Content

Drug Overview
Global Sales Assessment
Product Description
Mechanism of Action
Pharmacodynamic Properties 
Pharmacokinetic Properties
Marketed Details for the United States 
Marketed Details for the Europe
Patent Information 
Patent and Exclusivity Expiry Assessment United States (US)
Patent Numbers and Expiry Details
Patent Details
Route of Synthesis
Global API Manufacturers Assessment
The United States Drug Master File (US DMF)
The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF)
The Active Pharmaceutical Ingredient (API) Manufacturers in the ASIA Region
The Active Pharmaceutical Ingredient (API) Manufacturers by the United States Drug Master (DMF) File Status 
The Active Pharmaceutical Ingredient (API) Manufacturers by Region
The Active Pharmaceutical Ingredient (API) Manufacturers by Location/Countries
Generic Players
The Pipeline Coverage

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=218754

Competitive Landscape And Analysis Of Xtandi - Drug Insights For 2017

Researchmoz added Most up-to-date research on "Competitive Landscape And Analysis Of Xtandi - Drug Insights For 2017" to its huge collection of research reports.

The Report will be Dispatched in 3 working days. DelveInsights pharmaceuticals report, Xtandi - Drug Insights, 2014 provides Xtandi marketed details and API Manufacturers details across the globe along with the location. In addition, it covers sales estimates for the US, detailed clinical assessment of the drug, patent details, route of synthesis, competitive landscape, and analysis of sales performance during the forecast period (2011-2015). The report also includes SWOT analysis for the drug. This report is built using data and information sourced from DelveInsight proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by DelveInsight team of industry experts. 

Data Sources
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=218765

Table Of Content

Drug Overview
Global Sales Assessment
Product Description
Mechanism of Action
Pharmacodynamic Properties 
Pharmacokinetic Properties
Marketed Details for the United States 
Marketed Details for the Europe
Patent Information 
Patent and Exclusivity Expiry Assessment United States (US)
Patent Numbers and Expiry Details
Patent Details
Route of Synthesis
Global API Manufacturers Assessment
The United States Drug Master File (US DMF)
The Europe Drug Master File (EUDMF)/Active Substance Master File (ASMF)
The Active Pharmaceutical Ingredient (API) Manufacturers in the ASIA Region
The Active Pharmaceutical Ingredient (API) Manufacturers by the United States Drug Master (DMF) File Status 
The Active Pharmaceutical Ingredient (API) Manufacturers by Region
The Active Pharmaceutical Ingredient (API) Manufacturers by Location/Countries
Generic Players
The Pipeline Coverage
Clinical Trials Information
Clinical Trials by Zone
Company Profile
Summary
Company Financials
SWOT Analysis

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=218765

Various Stages Of Metastatic Pancreatic Cancer, Pipeline Review, H1 For 2017 | ResearchMoz

Researchmoz added Most up-to-date research on "Various Stages Of Metastatic Pancreatic Cancer, Pipeline Review, H1 For 2017 | ResearchMoz" to its huge collection of research reports.

Global Markets Directs, Metastatic Pancreatic Cancer Pipeline Review, H1 2015, provides an overview of the Metastatic Pancreatic Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

• The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects

Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=244737

• The report summarizes all the dormant and discontinued pipeline projects 
• A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics

To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=244737